Donor derived malignancy following transplantation: a review

Area of Science:

• Transplantation immunology
• Oncology
• Medical research

Background:

• Organ and tissue transplantation is a critical treatment for end-stage diseases.
• Increasing organ demand and limited supply lead to longer wait times and expanded donor criteria.
• Expanded donor criteria carry a risk of donor-derived malignancy.

Purpose of the Study:

• To review donor-related malignancies following solid organ transplantation and hematopoietic progenitor cell transplantation.
• To discuss the detection and management of donor-related malignancies.

Main Methods:

• Literature review of donor-derived malignancies in transplantation.
• Analysis of malignancy transmission and occurrence post-transplant.
• Review of diagnostic and therapeutic approaches.

Main Results:

• Malignancy post-transplantation can arise de novo, recur, or be donor-related.
• Donor-related malignancy involves direct tumor transmission or tumors arising from donor cells.
• Solid organ and hematopoietic progenitor cell transplant recipients are at risk.

Conclusions:

• Donor-derived malignancies pose a significant risk in transplantation, especially with expanded donor criteria.
• Early detection and appropriate management are crucial for patient outcomes.
• Further research is needed to refine screening and treatment protocols.